Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
38,915,007
-
Share change
-
+4,753,316
-
Total reported value
-
$767,771,992
-
Put/Call ratio
-
84%
-
Price per share
-
$19.73
-
Number of holders
-
152
-
Value change
-
+$97,416,660
-
Number of buys
-
82
-
Number of sells
-
69
Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2024
As of 31 Mar 2024,
Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by
152 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,915,007 shares.
The largest 10 holders included
BlackRock Inc., Fairmount Funds Management LLC, HHLR ADVISORS, LTD., VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, Rubric Capital Management LP, STATE STREET CORP, PICTET ASSET MANAGEMENT Holding SA, BRAIDWELL LP, and MORGAN STANLEY.
This page lists
152
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.